BioMerieux’s Growth Meets Our Expectations Despite Modest Slowdown
 BioMerieux’s third-quarter growth continued to mostly track our expectations, and we don’t anticipate a change in our fair value estimate or narrow-moat rating. This quarter’s 4.2% and 4.4% internal growth in the microbiology and immunoassay segments, respectively, came in a bit weaker than we anticipated and continue to show a modest slowdown in growth from the stronger performance see earlier this year. Regardless, the company’s molecular biology and industrial segment sales growth remained f...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.